181 Phospholamban R14del Cardiomyopathy: a systematic summary of the pathophysiological mechanisms 7 68. van de Leur, R. R. et al. Discovering and Visualizing Disease-Specific Electrocardiogram Features Using Deep Learning: Proof-of-Concept in Phospholamban Gene Mutation Carriers. Circ. Arrhythm. Electrophysiol. 14, e009056 (2021). 69. Lopes, R. R. et al. Improving electrocardiogram-based detection of rare genetic heart disease using transfer learning: An application to phospholamban p.Arg14del mutation carriers. Comput. Biol. Med. 131, 104262 (2021). 70. Nguyen, T. V. et al. Genetic Determinants and Genotype-Phenotype Correlations in Vietnamese Patients With Dilated Cardiomyopathy. Circ. J. 85, 1469–1478 (2021). 71. Feyen, D. A. M. et al. Unfolded Protein Response as a Compensatory Mechanism and Potential Therapeutic Target in PLN R14del Cardiomyopathy. Circulation (2021) doi:10.1161/CIRCULATIONAHA.120.049844. 72. Cuello, F. et al. Impairment of the ER/mitochondria compartment in human cardiomyocytes with PLN p.Arg14del mutation. EMBO Mol. Med. 13, e13074 (2021). 73. Raad, N. et al. Arrhythmia Mechanism and Dynamics in a Humanized Mouse Model of Inherited Cardiomyopathy Caused by Phospholamban R14del Mutation. Circulation 144, 441–454 (2021). 74. Verstraelen, T. E. et al. Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriersreaching the frontiers of individual risk prediction. Eur. Heart J. 42, 2842–2850 (2021). 75. Te Rijdt, W. P. et al. Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST). Neth. Heart J. (2021) doi:10.1007/s12471-021-01584-5. 76. Haghighi, K. et al. Impaired Right Ventricular Calcium Cycling Is an Early Risk Factor in R14del-Phospholamban Arrhythmias. J Pers Med 11, (2021). 77. Koch, D. et al. Molecular noise filtering in the β-adrenergic signaling network by phospholamban pentamers. Cell Rep. 36, 109448 (2021). 78. Grote Beverborg, N. et al. Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy. Nat. Commun. 12, 5180 (2021). 79. Taha, K. et al. Optimal echocardiographic assessment of myocardial dysfunction for arrhythmic risk stratification in phospholamban mutation carriers. Eur. Heart J. Cardiovasc. Imaging (2021) doi:10.1093/ehjci/jeab178. 80. Eijgenraam, T. R. et al. Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)-Related Cardiomyopathy: Development of PLN-R14del-Related Cardiomyopathy. Circ. Heart Fail. 14, e008532 (2021). 81. van der Klooster, Z. J. et al. P62-positive aggregates are homogenously distributed in the myocardium and associated with the type of mutation in genetic cardiomyopathy. J. Cell. Mol. Med. 25, (2021). 82. de Brouwer, R. et al. Sex-specific aspects of phospholamban cardiomyopathy: The importance and prognostic value of low-voltage electrocardiograms. Heart Rhythm (2021) doi:10.1016/j.hrthm.2021.11.009. 83. Kamel, S. M. et al. Istaroxime treatment ameliorates calcium dysregulation in a zebrafish model of phospholamban R14del cardiomyopathy. Nat. Commun. 12, 7151 (2021). 84. Tabata, T. et al. Phospholamban p.Arg14del Cardiomyopathy: A Japanese Case Series. Intern. Med. (2021) doi:10.2169/internalmedicine.8594-21. 85. Badone, B. et al. Characterization of the PLN p.Arg14del Mutation in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Int. J. Mol. Sci. 22, (2021). 86. de Boer, R. A. et al. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). Eur. J. Heart Fail. (2021) doi:10.1002/ ejhf.2414. 87. Driessen, H. E. et al. Buccal Mucosa Cells as a Potential Diagnostic Tool to Study Onset and Progression of Arrhythmogenic Cardiomyopathy. Int. J. Mol. Sci. 23, (2021). 88. van der Voorn, S. M. et al. Exploring the Correlation Between Fibrosis Biomarkers and Clinical Disease Severity in PLN p.Arg14del Patients. Front Cardiovasc Med 8, 802998 (2021). 89. Mittal, N. et al. Generation of human induced pluripotent stem cell (iPSC) lines derived from five patients carrying the pathogenic phospholamban-R14del (PLN-R14del) variant and three non-carrier family members. Stem Cell Res. 60, 102737 (2022).
RkJQdWJsaXNoZXIy MTk4NDMw